The report showcases evidence of the UK’s growing industry and infrastructure for manufacturing cell and gene therapies.

The Cell and Gene Therapy (CGT) Catapult has published its Good Manufacturing Practice (GMP) Manufacturing in the UK Report for 2018, which demonstrates the UK’s cell and gene therapy industry is strengthening through private and government investment. For instance, since November 2017 the UK has seen a 60% increase in manufacturing space for cell and gene therapies. This growth has in part derived from the opening of the CGT Catapult’s GMP manufacturing centre in Stevenage in April, as well as the expansion in facilities at Cobra Biologics and the Scottish National Blood Transfusion Centre.

Some other key statistics outlined in the report include the fact that there is to be a further 1,500m2 of cleanroom space coming online by the end of 2019, which would take the total cleanroom footprint to around 8,000m2. There has additionally been a 30% increase in employment over the past year with over 500 people currently employed in manufacturing in 21 organisations. The report suggests that this number is set to increase significantly as the industry grows and the number of therapies reaching commercialisation increases.

The fact that utilisation of capacity in these centres has risen by 4% to 81% suggests the increasing demand for cell and gene therapy services and infrastructure driven by the rapidly evolving pipeline of advanced therapies. Two of the 21 centres have commercial licences, as well as others holding Investigational Medicinal Product licences, which demonstrates the UK’s increasing position as a global destination for ATMP manufacturing and development.

You can view the original story here.

 

Download the full report here.

Share this article